Atorvastatin indications and usage: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
(Redirected page to Atorvastatin calcium)
Line 1: Line 1:
__NOTOC__
#REDIRECT [[Atorvastatin calcium]]
{{Atorvastatin}}
{{CMG}}; {{AE}} {{PB}}
 
==Indications and Usage==
 
Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to [[hypercholesterolemia]]. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and [[cholesterol]] and other nonpharmacologic measures alone has been inadequate. In patients with [[CHD]] or multiple risk factors for CHD, LIPITOR can be started simultaneously with diet.
 
====Prevention of Cardiovascular Disease====
 
In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, [[smoking]], [[hypertension]], low [[HDL]]-C, or a family history of early coronary heart disease, LIPITOR is indicated to:
 
* Reduce the risk of [[myocardial infarction]]
* Reduce the risk of [[stroke]]
* Reduce the risk for [[revascularization]] procedures and [[angina]]
 
In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as [[retinopathy]], [[albuminuria]], [[smoking]], or [[hypertension]], LIPITOR is indicated to:
 
* Reduce the risk of [[myocardial infarction]]
* Reduce the risk of [[stroke]]
 
In patients with clinically evident coronary heart disease, LIPITOR is indicated to:
 
* Reduce the risk of non-fatal [[myocardial infarction]]
* Reduce the risk of fatal and non-fatal [[stroke]]
* Reduce the risk for [[revascularization]] procedures
* Reduce the risk of hospitalization for [[CHF]]
* Reduce the risk of [[angina]]
 
====Hyperlipidemia====
 
LIPITOR is indicated:
 
* As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary [[hypercholesterolemia]] (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb);
 
* As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV);
 
* For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet;
 
* To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable;
 
* As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present:
 
: [[LDL]]-C remains ≥ 190 mg/dL or
: [[LDL]]-C remains ≥ 160 mg/dL and:
:: a) there is a positive family history of premature cardiovascular disease
:: b) or two or more other CVD risk factors are present in the pediatric patient
 
====Limitations of Use====
 
LIPITOR has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V).<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = LIPITOR (ATORVASTATIN CALCIUM) TABLET, FILM COATED [PARKE-DAVIS DIV OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228 | publisher =  | date =  | accessdate = }}</ref>
 
==References==
 
{{Reflist}}
 
{{FDA}}
 
[[Category:Cardiovascular Drugs]]
[[Category:Drugs]]

Revision as of 13:46, 21 July 2014